No Data
Mingke Pharmaceutical (688373): Achieves record quarterly revenue, pipeline development reaches milestone.
Event: The company released the third quarter report for 2024, achieving an income of 97.56 million yuan for the first three quarters (+42.9%), with a net income attributable to the mother of -0.29 billion yuan. Conterazole's quarterly sales hit a new high. Looking at each quarter, the company's Q1/
MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia
Shanghai Mengke Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Express News | Mingke Pharmaceutical: MRX-5 Phase I clinical trial in Australia successful.
Medytox (688373.SH): The proposed investment amount in MicuRx Pharmaceuticals, Inc. is adjusted from $80 million to $60 million.
On October 9th, Geelong announced that Mengke Pharmaceuticals (688373.SH) plans to adjust the investment amount in MicuRx Pharmaceuticals, Inc. from $80 million to $60 million, with the contribution method still being cash investment. The company will, based on the funding situation, authorize management to implement the capital increase scheme in batches with its own or self-raised funds after completing the corresponding approval procedures.
Mengke Pharmaceutical: Achieved revenue of 60.74 million yuan in the first half of 2024, a year-on-year increase of 44%.
In the first half of 2024, the revenue reached 60.7382 million yuan, a year-on-year growth of 44.24%. The R&D investment reached 166.1674 million yuan, a year-on-year growth of 72.91%; the R&D investment accounted for 273.58% of revenue, an increase of 45.37 percentage points compared to the same period last year. Shanghai, September 2, 2024 / PRNewswire / - On August 29, 2024, Shanghai Mengke Pharmaceutical Co., Ltd. ("Mengke Pharmaceuticals", 688373.SH) disclosed its semi-annual report for 2024. During the reporting period, the company achieved revenue of 60.7382 million yuan, a year-on-year growth.
No Data
No Data